
A recent study delved into the impact of metabolic co-morbidities (MetC) on the effectiveness of non-selective beta-blockers (NSBBs) in patients with compensated advanced chronic liver disease (cACLD). Among the 92 patients analyzed, 37% had MetC, including obesity, dyslipidemia, and diabetes. The study found that patients with diabetes and a higher body mass index (BMI) were less likely to respond positively to NSBB therapy, which helps reduce hepatic decompensation risk. Diabetes, independent of other factors, was also linked to an increased risk of hepatic decompensation. These findings highlight the importance of tailored treatment approaches for cACLD patients with MetC.
Like
Save
Share